#USA #Piramal Pharma #bioconjugates #US Expansion #Kentucky, Michigan

Piramal Pharma's Strategic Investment in U.S. Facilities

Piramal Pharma Limited (NSE: PPLPHARMA) is poised to significantly strengthen its presence in the U.S. pharmaceutical market with a noteworthy investment plan. Announced in conjunction with the 2025 SelectUSA Investment Summit, the company has committed $90 million towards enhancing two key facilities located in Lexington, Kentucky, and Riverview, Michigan. This initiative builds on Piramal's previous investment of $570 million in U.S. drug development and manufacturing capabilities, reflecting a strategic decision to cater to growing demands from U.S. customers and support the trend of onshoring drug supplies.

Expansion Plans in Detail

The Lexington facility, known for its expertise in sterile compounding and drug formulation, will undergo a substantial expansion that adds 24,000 square feet of manufacturing space. This enhancement includes the introduction of a new laboratory, a vital step towards bolstering commercial-scale sterilization processes for injectable drug products. This expansion will see the installation of additional equipment, including a new filling line, two commercial-size lyophilizers, a sophisticated capping machine, and an external vial washer. Completion of this project is expected by late 2027.

Meanwhile, the Riverview facility has earned accolades over the past five decades for its leadership in the production of active pharmaceutical ingredients (APIs), especially focusing on high potency APIs. The new addition here will feature a dedicated suite for the development and production of payload-linkers used in antibody-drug conjugates (ADCs) and other bioconjugate therapies, with the suite slated to commence operations by the end of 2025.

Meeting Market Demands

Both expansions are anticipated to generate increased opportunities for integrated ADC projects. The dual operational capabilities at these sites will enhance Piramal Pharma's ADCelerate™ program, streamlining timelines from project initiation to Good Manufacturing Practices (GMP) compliant drug product delivery in merely 12 months without compromising quality. Peter DeYoung, CEO of Piramal Global Pharma, stated, “The U.S. is our largest market, and this expansion is essential to supporting our existing customer base who prioritize our offerings in a domestic context.”

Piramal Pharma is committed to patient-centric operations, focusing on minimizing the burden of disease through efficient drug manufacturing and development. Both facilities will enable faster turnarounds for drug preparations essential for treating various health conditions, especially in oncology, where payload-linkers serve as critical components of bioconjugate drugs. The sterile fill/finish expansion is equally crucial as it represents the final manufacturing stage for injectable drugs, ensuring they are safely packaged and ready for distribution.

A Bright Future Ahead

Piramal Pharma Limited operates from a robust infrastructure composed of 17 global development and manufacturing sites catering to over 100 countries. With dedicated segments including Piramal Pharma Solutions, Piramal Critical Care, and consumer healthcare, the company is well-positioned to maintain its status as a leading player in the pharmaceutical industry. The expansion into Lexington and Riverview not only reinforces this position but also symbolizes a strategic alignment with the growing U.S. market demands for quicker and more efficient drug delivery systems.

As these facilities ramp up their capabilities, Piramal Pharma is set to continue paving the way in drug development innovation, fulfilling its commitment to enhancing patient care through superior pharmaceutical solutions.